Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 07:02 ET | Source: Ocugen

Ocugen to Present at April 2026 Investor and Industry Conferences

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
April 22, 2026 07:00 ET | Source: Coave Therapeutics

Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will...
April 21, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company...
April 21, 2026 08:00 ET | Source: Spur Therapeutics

Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium

Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
April 21, 2026 06:10 ET | Source: Research and Markets

Chronic Granulomatous Disease (CGD) Market Analysis and Outlook Report 2026-2036 - Emerging Gene Therapies, Lentiviral Vector-based Therapies and CRISPR-Cas9 Gene Editing, Ignite Hope

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Chronic Granulomatous Disease Market: Focus on Treatment Type, Route of Administration, Distribution Channel, Country and Regional Analysis,...
April 20, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 17, 2026 15:00 ET | Source: Asgard Therapeutics

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Asgard Therapeutics to present a poster on its lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026.
April 16, 2026 07:57 ET | Source: Research and Markets

Gene Therapy Market Report 2026-2034 - CRISPR and AAV Technologies Propel Gene Therapy Advancements; Global Market Growing at 12.27% CAGR

Dublin, April 16, 2026 (GLOBE NEWSWIRE) -- The "Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2026-2034" has been added to...
April 15, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 14, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...